"Hyperphosphatemia/drug therapy"[MAJR] - Search Results

Year	Number of Results
1990	1
2007	7
2008	27
2009	30
2010	36
2011	19
2012	20
2013	46
2014	53
2015	28
2016	28
2017	28
2018	19
2019	20
2020	24
2021	33
2022	34
2023	25
2024	20
2025	15

1

Barbar T, Jaffer Sathick I. Barbar T, et al. Adv Chronic Kidney Dis. 2021 Sep;28(5):438-446.e1. doi: 10.1053/j.ackd.2021.09.007. Adv Chronic Kidney Dis. 2021. PMID: 35190110 Review.

2

Dietary Therapy for Managing Hyperphosphatemia.

Narasaki Y, Rhee CM. Narasaki Y, et al. Clin J Am Soc Nephrol. 2020 Dec 31;16(1):9-11. doi: 10.2215/CJN.18171120. Clin J Am Soc Nephrol. 2020. PMID: 33380472 Free PMC article. No abstract available.

3

Long-term safety and decrease of pill burden by tenapanor therapy: a phase 3 open-label study in hemodialysis patients with hyperphosphatemia.

Koiwa F, Sato Y, Ohara M, Nakanishi K, Fukagawa M, Akizawa T. Koiwa F, et al. Sci Rep. 2023 Nov 4;13(1):19100. doi: 10.1038/s41598-023-45080-9. Sci Rep. 2023. PMID: 37925471 Free PMC article. Clinical Trial.

4

Meta-analysis of the efficacy and safety of sevelamer as hyperphosphatemia therapy for hemodialysis patients.

Zeng Q, Zhong Y, Yu X. Zeng Q, et al. Ren Fail. 2023 Dec;45(1):2210230. doi: 10.1080/0886022X.2023.2210230. Ren Fail. 2023. PMID: 37272189 Free PMC article. Review.

5

Tenapanor: First Approval.

Markham A. Markham A. Drugs. 2019 Nov;79(17):1897-1903. doi: 10.1007/s40265-019-01215-9. Drugs. 2019. PMID: 31677150 Review.

6

A Randomized Trial of Tenapanor and Phosphate Binders as a Dual-Mechanism Treatment for Hyperphosphatemia in Patients on Maintenance Dialysis (AMPLIFY).

Pergola PE, Rosenbaum DP, Yang Y, Chertow GM. Pergola PE, et al. J Am Soc Nephrol. 2021 Jun 1;32(6):1465-1473. doi: 10.1681/ASN.2020101398. Epub 2021 Mar 25. J Am Soc Nephrol. 2021. PMID: 33766811 Free PMC article. Clinical Trial.

7

[Phosphate binders].

Heeb RM. Heeb RM. Med Monatsschr Pharm. 2016 Jun;39(6):255-60. Med Monatsschr Pharm. 2016. PMID: 27439258 Review. German.

8

Tenapanor: A Phosphate Absorption Inhibitor for the Management of Hyperphosphatemia in Patients With Kidney Failure.

Hill Gallant KM, Sprague SM, Rosenbaum DP, Spiegel DM, Kozuka K, Edelstein S, Chertow GM. Hill Gallant KM, et al. J Ren Nutr. 2025 Jan;35(1):25-34. doi: 10.1053/j.jrn.2024.07.003. Epub 2024 Jul 9. J Ren Nutr. 2025. PMID: 38992521 Free article. Review.

9

Non-Uremic Calciphylaxis.

Holtsche MM, Zillikens D, Shimanovich I. Holtsche MM, et al. Dtsch Arztebl Int. 2018 Apr 13;115(15):265. doi: 10.3238/arztebl.2018.0265. Dtsch Arztebl Int. 2018. PMID: 29735007 Free PMC article. No abstract available.

10

Effect of Treating Hyperphosphatemia With Lanthanum Carbonate vs Calcium Carbonate on Cardiovascular Events in Patients With Chronic Kidney Disease Undergoing Hemodialysis: The LANDMARK Randomized Clinical Trial.

Ogata H, Fukagawa M, Hirakata H, Kagimura T, Fukushima M, Akizawa T; LANDMARK Investigators and Committees. Ogata H, et al. JAMA. 2021 May 18;325(19):1946-1954. doi: 10.1001/jama.2021.4807. JAMA. 2021. PMID: 34003226 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

440 results

Results by year

Search Page

Filters

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

440 results

Results by year